MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma.
A genetic marker predicts shorter survival in multiple myeloma, enabling doctors to identify higher-risk patients and tailor treatment intensity.
MYC rearrangement is an independent predictor of shorter PFS (HR 1.96, p=0.007) in newly diagnosed MM; integrating MYC-R into the double-hit model increases concordance index for PFS from 0.549 to 0.581; IgH/MYC fusion associated with worst outcomes. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective cohort (NICHE clinical trial, NCT04645199)
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- ESMO Open
Why it surfaced
Prospective clinical validation of MYC-R as an independent biomarker and risk model enhancer for newly diagnosed MM; directly actionable for FISH panel design and treatment stratification; ESMO Open (peer-reviewed OA oncology journal); large enough cohort for meaningful hazard ratio estimation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.